Repositioning Candidate Details
| Candidate ID: | R0040 |
| Source ID: | DB00129 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Ornithine |
| Synonyms: | (S)-2,5-Diaminopentanoate; (S)-2,5-Diaminopentanoic acid; (S)-2,5-diaminovaleric acid; (S)-ornithine; (S)-α,δ-diaminovaleric acid; L-Ornithine; levo-ornithine; Ornithine |
| Molecular Formula: | C5H12N2O2 |
| SMILES: | NCCC[C@H](N)C(O)=O |
| Structure: |
|
| DrugBank Description: | Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine. |
| CAS Number: | 70-26-8 |
| Molecular Weight: | 132.161 |
| DrugBank Indication: | Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing. |
| DrugBank Pharmacology: | A non-essential and nonprotein amino acid, ornithine is critical for the production of the body's proteins, enzymes and muscle tissue. Ornithine plays a central role in the urea cycle and is important for the disposal of excess nitrogen (ammonia). Ornithine is the starting point for the synthesis of many polyamines such as putrescine and spermine. Ornithine supplements are claimed to enhance the release of growth hormone and to burn excess body fat. Ornithine is necessary for proper immune function and good liver function. |
| DrugBank MoA: | L-Ornithine is metabolised to L-arginine. L-arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of L-arginine in tissues throughout the body. As De novo synthesis of L-arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, L-ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to L-arginine). |
| Targets: | Ornithine aminotransferase, mitochondrial; Ornithine carbamoyltransferase, mitochondrial; Arginase-1; Ornithine decarboxylase antizyme 1; High affinity cationic amino acid transporter 1; Low affinity cationic amino acid transporter 2; Mitochondrial ornithine transporter 2; Arginase-2, mitochondrial; Mitochondrial ornithine transporter 1; Glycine amidinotransferase, mitochondrial |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 5113 | Nutritional deficiency disease | A nutrition disease that is characterized by deficiency of a nutritional element, such as a vitamin, mineral, carbohydrate, protein, fat, or general energy content. https://medlineplus.gov/malnutrition.html | disease of metabolism/acquired metabolic disease/nutrition disease | Details |